Literature DB >> 29948642

Metabolic Imaging Phenotype Using Radiomics of [18F]FDG PET/CT Associated with Genetic Alterations of Colorectal Cancer.

Shang-Wen Chen1,2,3, Wei-Chih Shen4, William Tzu-Liang Chen2,5, Te-Chun Hsieh6,7, Kuo-Yang Yen6,7, Jan-Gowth Chang2,8, Chia-Hung Kao9,10,11.   

Abstract

PURPOSE: To understand the association between genetic mutations and radiomics of 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET)/x-ray computed tomography (CT) in patients with colorectal cancer (CRC). PROCEDURES: This study included 74 CRC patients who had undergone preoperative [18F]FDG PET/CT. A total of 65 PET/CT-related features including intensity, volume-based, histogram, and textural features were calculated. High-resolution melting methods were used for genetic mutation analysis.
RESULTS: Genetic mutants were found in 21 KRAS tumors (28 %), 31 TP53 tumors (42 %), and 17 APC tumors (23 %). Tumors with a mutated KRAS had an increased value at the 25th percentile of maximal standardized uptake value (SUVmax) within their metabolic tumor volume (MTV) (P < .0001; odds ratio [OR] 1.99; 95 % confidence interval [CI] 1.37-2.90) and their contrast from the gray-level cooccurrence matrix (P = .005; OR 1.52; 95 % CI 1.14-2.04). A mutated TP53 was associated with an increased value of short-run low gray-level emphasis derived from the gray-level run length matrix (P = .001; OR 243006.0; 95 % CI 59.2-996,872,313). APC mutants exhibited lower low gray-level zone emphasis derived from the gray-level zone length matrix (P = .006; OR < .0001; 95 % CI 0.000-0.22).
CONCLUSION: PET/CT-derived radiomics can provide supplemental information to determine KRAS, TP53, and APC genetic alterations in CRC.

Entities:  

Keywords:  Colorectal cancer (CRC); Mutations; Positron emission tomography computed tomography (PET/CT); Radiomics

Mesh:

Substances:

Year:  2019        PMID: 29948642     DOI: 10.1007/s11307-018-1225-8

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  26 in total

1.  Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.

Authors:  Jantine L Westra; Michael Schaapveld; Harry Hollema; Jelle P de Boer; Marian M J Kraak; Debora de Jong; Arja ter Elst; Nanno H Mulder; Charles H C M Buys; Robert M W Hofstra; John T M Plukker
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

2.  Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells.

Authors:  Jihye Yun; Carlo Rago; Ian Cheong; Ray Pagliarini; Philipp Angenendt; Harith Rajagopalan; Kerstin Schmidt; James K V Willson; Sandy Markowitz; Shibin Zhou; Luis A Diaz; Victor E Velculescu; Christoph Lengauer; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos
Journal:  Science       Date:  2009-08-06       Impact factor: 47.728

3.  The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma.

Authors:  A Conlin; G Smith; F A Carey; C R Wolf; R J C Steele
Journal:  Gut       Date:  2005-04-20       Impact factor: 23.059

4.  Cellular metabolic responses of PET radiotracers to (188)Re radiation in an MCF7 cell line containing dominant-negative mutant p53.

Authors:  Gi Jeong Cheon; Hye-Kyung Chung; Jung-A Choi; Su-Jae Lee; Soon-Hyuk Ahn; Tae-Sup Lee; Chang Woon Choi; Sang Moo Lim
Journal:  Nucl Med Biol       Date:  2007-03-30       Impact factor: 2.408

5.  Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.

Authors:  Stephen S F Yip; John Kim; Thibaud P Coroller; Chintan Parmar; Emmanuel Rios Velazquez; Elizabeth Huynh; Raymond H Mak; Hugo J W L Aerts
Journal:  J Nucl Med       Date:  2016-09-29       Impact factor: 10.057

6.  (18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status.

Authors:  Pierre Lovinfosse; Benjamin Koopmansch; Frederic Lambert; Sébastien Jodogne; Gaelle Kustermans; Mathieu Hatt; Dimitris Visvikis; Laurence Seidel; Marc Polus; Adelin Albert; Philippe Delvenne; Roland Hustinx
Journal:  Br J Radiol       Date:  2016-05-05       Impact factor: 3.039

7.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

8.  Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas.

Authors:  Amy Leslie; Norman R Pratt; Karen Gillespie; Mark Sales; Neil M Kernohan; Gillian Smith; C Roland Wolf; Francis A Carey; Robert J C Steele
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

Review 9.  P53 abnormalities and outcomes in colorectal cancer: a systematic review.

Authors:  A J Munro; S Lain; D P Lane
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

Review 10.  American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Authors:  Carmen J Allegra; J Milburn Jessup; Mark R Somerfield; Stanley R Hamilton; Elizabeth H Hammond; Daniel F Hayes; Pamela K McAllister; Roscoe F Morton; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

View more
  13 in total

1.  Preoperative prediction of regional lymph node metastasis of colorectal cancer based on 18F-FDG PET/CT and machine learning.

Authors:  Jiahong He; Quanshi Wang; Yin Zhang; Hubing Wu; Yongsheng Zhou; Shuangquan Zhao
Journal:  Ann Nucl Med       Date:  2021-03-18       Impact factor: 2.668

Review 2.  Radiogenomics Based on PET Imaging.

Authors:  Yong-Jin Park; Mu Heon Shin; Seung Hwan Moon
Journal:  Nucl Med Mol Imaging       Date:  2020-05-09

Review 3.  Radiomics in Oncological PET Imaging: A Systematic Review-Part 2, Infradiaphragmatic Cancers, Blood Malignancies, Melanoma and Musculoskeletal Cancers.

Authors:  David Morland; Elizabeth Katherine Anna Triumbari; Luca Boldrini; Roberto Gatta; Daniele Pizzuto; Salvatore Annunziata
Journal:  Diagnostics (Basel)       Date:  2022-05-27

Review 4.  Radiomics-Guided Precision Medicine Approaches for Colorectal Cancer.

Authors:  Mohammed I Quraishi
Journal:  Front Oncol       Date:  2022-06-09       Impact factor: 5.738

5.  A computed tomography (CT)-derived radiomics approach for predicting primary co-mutations involving TP53 and epidermal growth factor receptor (EGFR) in patients with advanced lung adenocarcinomas (LUAD).

Authors:  Ying Zhu; Yu-Biao Guo; Di Xu; Jing Zhang; Zhen-Guo Liu; Xi Wu; Xiao-Yu Yang; Dan-Dan Chang; Min Xu; Jing Yan; Zun-Fu Ke; Shi-Ting Feng; Yang-Li Liu
Journal:  Ann Transl Med       Date:  2021-04

6.  Predicting pathological complete response in rectal cancer after chemoradiotherapy with a random forest using 18F-fluorodeoxyglucose positron emission tomography and computed tomography radiomics.

Authors:  Wei-Chih Shen; Shang-Wen Chen; Kuo-Chen Wu; Peng-Yi Lee; Chun-Lung Feng; Te-Chun Hsieh; Kuo-Yang Yen; Chia-Hung Kao
Journal:  Ann Transl Med       Date:  2020-03

Review 7.  What can artificial intelligence teach us about the molecular mechanisms underlying disease?

Authors:  Gary J R Cook; Vicky Goh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-12       Impact factor: 9.236

8.  KRAS mutation effects on the 2-[18F]FDG PET uptake of colorectal adenocarcinoma metastases in the liver.

Authors:  M Popovic; O Talarico; J van den Hoff; H Kunin; Z Zhang; D Lafontaine; S Dogan; J Leung; E Kaye; C Czmielewski; M E Mayerhoefer; P Zanzonico; R Yaeger; H Schöder; J L Humm; S B Solomon; C T Sofocleous; A S Kirov
Journal:  EJNMMI Res       Date:  2020-11-23       Impact factor: 3.138

9.  Performance of Multiparametric Functional Imaging and Texture Analysis in Predicting Synchronous Metastatic Disease in Pancreatic Ductal Adenocarcinoma Patients by Hybrid PET/MR: Initial Experience.

Authors:  Jing Gao; Xinyun Huang; Hongping Meng; Miao Zhang; Xiaozhe Zhang; Xiaozhu Lin; Biao Li
Journal:  Front Oncol       Date:  2020-02-25       Impact factor: 6.244

10.  Clinical Significance and Prognostic Value of the Maximum Standardized Uptake Value of 18F-Flurodeoxyglucose Positron Emission Tomography-Computed Tomography in Colorectal Cancer.

Authors:  Yi-Xin Yin; Ming-Zhi Xie; Xin-Qiang Liang; Meng-Ling Ye; Ji-Lin Li; Bang-Li Hu
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.